Is Innovent Biologics (SEHK:1801) Fairly Valued On LP 003 China BLA Progress?

Simply Wall St.09-15 23:26

The National Medical Products Administration has accepted LongBio Pharma’s Biologics License Application for LP-003, supported by Innovent Biologics (SEHK:1801) subsidiary Altruist Biologics, marking ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2668822938?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","is_english":true,"pubTime":"2026-09-15 23:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2668822938","market":"sg","top_or_hot":-1,"title":"Is Innovent Biologics (SEHK:1801) Fairly Valued On LP 003 China BLA Progress?","media":"Simply Wall St.","content":"<div>\n<p>The National Medical Products Administration has accepted LongBio Pharma’s Biologics License Application for LP-003, supported by Innovent Biologics (SEHK:1801) subsidiary Altruist Biologics, marking ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/is-innovent-biologics-sehk1801-fairly-valued-on-lp-003-china\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Innovent Biologics (SEHK:1801) Fairly Valued On LP 003 China BLA Progress?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Innovent Biologics (SEHK:1801) Fairly Valued On LP 003 China BLA Progress?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-09-15 23:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/is-innovent-biologics-sehk1801-fairly-valued-on-lp-003-china><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The National Medical Products Administration has accepted LongBio Pharma’s Biologics License Application for LP-003, supported by Innovent Biologics (SEHK:1801) subsidiary Altruist Biologics, marking ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/is-innovent-biologics-sehk1801-fairly-valued-on-lp-003-china\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2097828805.USD","symbol_name":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/is-innovent-biologics-sehk1801-fairly-valued-on-lp-003-china","article_id":"2668822938","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/is-innovent-biologics-sehk1801-fairly-valued-on-lp-003-china","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2668822938","pubTimestamp":1789485964,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"The National Medical Products Administration has accepted LongBio Pharma’s Biologics License Application for LP-003, supported by Innovent Biologics (SEHK:1801) subsidiary Altruist Biologics, marking China’s first anti-IgE BLA for seasonal allergic rhinitis.\nFor investors tracking Innovent Biologics, the latest regulatory milestone lands after a mixed stretch in the market, with the share price slipping 1.9% over the last session and 5.2% across the week, yet recording a 26.9% 90 day share...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU0463099449.HKD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" (HKD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK1583":"高瓴概念","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","01801":"信达生物","LU0607220059.USD":"SCHRODER ISF HONG KONG EQUITY \"A\" (USD) ACC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","BK1589":"北水核心资产","LU1188198961.HKD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" (HKD) INC QV","PRGS":"Progress Software Corporation","BK4097":"系统软件","LU0244354667.USD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" ACC","BK1161":"生物科技","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","KURE":"KraneShares MSCI All China Health Care Index ETF","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU1831875114.USD":"SCHRODER ISF ALL CHINA EQUITY \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU0149534421.HKD":"SCHRODER ISF HONG KONG EQ \"A\" ACC"},"translate_title":"信达生物 (SEHK:1801) 对 LP 003 China BLA Progress 的估值是否合理？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KURE":0.6,"01801":0.9,"PRGS":1.5,"DCF":1},"content_text":"The National Medical Products Administration has accepted LongBio Pharma’s Biologics License Application for LP-003, supported by Innovent Biologics (SEHK:1801) subsidiary Altruist Biologics, marking China’s first anti-IgE BLA for seasonal allergic rhinitis. For investors tracking Innovent Biologics, the latest regulatory milestone lands after a mixed stretch in the market, with the share price slipping 1.9% over the last session and 5.2% across the week, yet recording a 26.9% 90 day share price return and a 140.2% three year total shareholder return that point to stronger momentum over the longer haul. Scan 619 high quality undiscovered gems with similar biologics exposure to Innovent Biologics so you can see which other developers are quietly building momentum behind the headlines. For Innovent Biologics, the recent pullback clashes with stronger multi year returns and fresh regulatory progress. Is pricing now tracking the underlying business, or is it simply reflecting a shift in sentiment as investors reassess value? AdvertisementPreferred P/E of 114.8x for Innovent Biologics: Is it justified? On price, Innovent Biologics is not cheap by simple earnings metrics. The stock closed at HK$95, while the latest checks show a P/E of 114.8x that sits well above several key reference points. P/E compares what investors are paying today for each unit of current earnings. For a research led biopharma group like Innovent Biologics, a high P/E often reflects expectations that profits will expand meaningfully as its drug portfolio matures and new therapies reach scale. Analysts are currently in agreement that the share price could rise from here, with the target price sitting 35.8% above the last close and the stock also trading 36.7% below an internal fair value estimate based on future cash flows. That points to a market willing to pay a steep multiple today, while still pricing the shares below other valuation anchors that are focused on earnings and revenue forecasts. The comparison with peers is stark. Management is running a P/E of 114.8x against a Hong Kong Biotechs industry average of 17.7x and a peer group average of 25.4x. The fair P/E ratio implied by regression based analysis sits at 35.1x, which is far lower than where the shares trade now and suggests the earnings multiple could move closer to that level if expectations cool. Explore the SWS fair ratio for Innovent Biologics. Result: Price-to-Earnings of 114.8x (OVERVALUED) Still, any stumble in LP-003’s approval process or slower adoption of Innovent Biologics’ commercial portfolio could quickly challenge the rich 114.8x P/E narrative. Find out about the key risks to this Innovent Biologics narrative. Another View on Innovent Biologics' Valuation The high P/E for Innovent Biologics paints one picture. The SWS DCF model tells a different story. On that framework, the shares at HK$95 are trading below an estimated future cash flow value of HK$150, which points to a sizeable discount rather than excess. That gap means P/E multiples are flagging valuation risk while the cash flow work suggests potential upside. You are effectively choosing which set of assumptions to trust more: the near term earnings snapshot or the longer term cash generation. Which lens feels more realistic for a drug developer still building out its portfolio? Look into how the SWS DCF model arrives at its fair value. 1801 Discounted Cash Flow as at Sep 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Innovent Biologics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 196 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps Strong opinions run both ways in this Innovent Biologics story. Check the numbers yourself, move quickly, and weigh the upside that others are already watching in the 4 key rewards Looking for more Innovent Biologics investment ideas? If you like the setup around Innovent Biologics but do not want to rely on a single story, cast the net wider using focused stock lists.  Target potential mispricing by scanning a curated pool of quality opportunities through the 196 high quality undervalued stocks. Build resilience into your portfolio by focusing on companies screened for strong finances in the list of solid balance sheet and fundamentals (195 results). Dial down volatility and concentrate on stability by filtering opportunities inside the 103 resilient stocks with low risk scores.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2668822938","isCrawlerRequest":true}